160701-50-8Relevant academic research and scientific papers
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Page/Page column 39, (2014/10/18)
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. Formule (I)
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Page/Page column 74, (2014/10/15)
The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Page/Page column 61, (2014/10/15)
The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
Selective removal of phenolic and alcoholic silyl ethers
Prakash, Chandra,Saleh, Samir,Blair, Lan A.
, p. 7565 - 7568 (2007/10/02)
Potassium carbonate/Kriptofix 222 and pyridinium p-toluenesulfonate or BF3-etherate have been found to remove the tert-butyldimethylsilyl group from phenolic and alcoholic silyl ethers, respectively. This methodology should find wide applicability in complex organic synthesis.
